ADAM17 and neoplasm: Thus, pharmacological modulation of iRHOM2 by targeting two stress-response proteins, K16 and ADAM17, could provide a specific therapeutic strategy in the treatment of PPK's, inflammatory epithelial disease and neoplasia.